AKR1E2
1,5-anhydro-D-fructose reductase
Also known as: AKCL2_HUMAN, AKR1CL2, AKRDC1, htAKR, HTSP1, MGC10612
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96JD6
- Gene
- AKR1E2
- Ensembl
- ENSG00000165568
- Chromosome
- 10
- Canonical length
- 320 aa
- Protein class
- Enzymes, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Golgi apparatus,Cytosol
OverviewNCBI Gene
The protein encoded by this gene is a member of the aldo-keto reductase superfamily. Members in this family are characterized by their structure (evolutionarily highly conserved TIM barrel) and function (NAD(P)H-dependent oxido-reduction of carbonyl groups). Transcripts of this gene have been reported in specimens of human testis. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2012]
Canonical amino-acid sequenceUniProt
320 residues, UniProt reviewed canonical sequence.
>Q96JD6|AKR1E2
1 MGDIPAVGLS SWKASPGKVT EAVKEAIDAG YRHFDCAYFY HNEREVGAGI RCKIKEGAVR
61 REDLFIATKL WCTCHKKSLV ETACRKSLKA LKLNYLDLYL IHWPMGFKPP HPEWIMSCSE
121 LSFCLSHPRV QDLPLDESNM VIPSDTDFLD TWEAMEDLVI TGLVKNIGVS NFNHEQLERL
181 LNKPGLRFKP LTNQIECHPY LTQKNLISFC QSRDVSVTAY RPLGGSCEGV DLIDNPVIKR
241 IAKEHGKSPA QILIRFQIQR NVIVIPGSIT PSHIKENIQV FDFELTQHDM DNILSLNRNL
301 RLAMFPITKN HKDYPFHIEYLocalizationUniProt · AlphaFold · HPA
Whether an antibody against AKR1E2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 17 nTPM
Expression across tissuesHPA
Tissue
- testis: 17 nTPM
- retina: 3.1 nTPM
- thyroid gland: 3.1 nTPM
- breast: 2.8 nTPM
- bone marrow: 2 nTPM
- pancreas: 2 nTPM
Single-cell type
- late spermatids: 258 nCPM
- early spermatids: 228 nCPM
- late primary spermatocytes: 102 nCPM
- early primary spermatocytes: 79 nCPM
- retinal horizontal cells: 54 nCPM
- retinal ganglion cells: 50 nCPM
Immune cell
- basophil: 0.9 nTPM
- myeloid DC: 0.4 nTPM
- plasmacytoid DC: 0.4 nTPM
- naive CD4 T-cell: 0.3 nTPM
- classical monocyte: 0.1 nTPM
- memory CD4 T-cell: 0.1 nTPM
Brain region
- medulla oblongata: 12 nTPM
- hypothalamus: 11 nTPM
- pons: 11 nTPM
- cerebral cortex: 10 nTPM
- midbrain: 10 nTPM
- thalamus: 9.3 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.42
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.31
- DepMap mean gene effect
- 0.13
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- aldose reductase (NADPH) activity
- oxidoreductase activity
- 1,5-anhydro-D-fructose reductase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads AKR1E2 as an antibody target. Whether an autoantibody or antibody against AKR1E2 could matter depends on whether native AKR1E2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
AKR1E2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label AKR1E2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...